[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534965":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":34,"responsibleParty":58,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Transgender women",null,"Transgender individuals assigned male at birth undergoing estrogen and antiandrogen hormone therapy",[13],"Drug: gender affirming hormone therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Transgender men","Transgender individuals assigned female at birth undergoing testosterone hormone therapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","gender affirming hormone therapy","both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio",[15,9],[25,31],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Carola Deischinger, MD PhD","CONTACT","+43140400","20690","carola.deischinger@meduniwien.ac.at",{"name":32,"role":27,"phone":28,"phoneExt":29,"email":33},"Alexandra Kautzky-Willer, Prof., MD","alexandra.kautzky-willer@meduniwien.ac.at",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Chiari Stoffwechselambulanz, Medical University of Vienna","RECRUITING","Vienna","State of Vienna","1090","Austria","AT",{"type":44,"coordinates":45},"Point",[46,47],16.37208,48.20849,{"lat":47,"lon":46},[50,51,53,55],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":52,"role":27,"phone":28,"phoneExt":29,"email":33},"Alexandra Kautzky-Willer, Prof, MD",{"name":26,"role":54,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":56,"role":57,"phone":10,"phoneExt":10,"email":10},"Alexandra Kautzky-Willer, Prof Dr","PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Alexandra Kautzky-Willer","Principal Investigator","100534965","effects-of-cross-sex-hormone-treatment-on-cardiac-function-myocardial-and-hepatic-fat-content-100534965",false,"NCT06245681","Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content","Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content, Its (Anti)-Atherogenic Implications and Effects on the Insulin System: a Pilot Study","Inclusion Criteria:\n\n* DSM-IV diagnosis of Gender Identity Disorder\n* age over 18 years\n\nExclusion Criteria:\n\n* age under 18 years severe neurological or internal diseases\n\n  * steroid hormone treatment within 2 months prior to inclusion (including birth control pill, phytohormones)\n  * treatment with psychotropic agents such as SSRIs\n  * any implant or stainless-steel graft\n  * abnormal values in routine laboratory screening or general physical examination\n  * current substance abuse (determined using drug screening at the screening visit)\n  * pregnancy (determined at screening visit and first MRI scan)\n  * failure to comply with the study protocol or to follow the instructions of the investigating",true,"ALL","18 Years","99 Years",{"count":73,"type":74},40,"ESTIMATED","OBSERVATIONAL","Background: Sex hormones are believed to play an important role in the development and progression of cardiovascular disease. However, the gender gap in onset and mortality is not yet completely understood. Transsexuals undergoing hormone therapy are a promising collective for analyzing the effects of sex hormones on atherosclerosis and other cardiovascular disease. Objectives of the study: To identify gender-specific cardiovascular changes attributed to high-dose hormone therapy in male-to-female (MtF) and female-to-male(FtM) transgender using sonography and magnet resonance spectroscopy. Study design: Longitudinal cohort study. Transsexuals will undergo two 3 Tesla MRI scan sessions: 1. baseline (before hormone treatment) and 2. after 6 months of treatment. An oral glucose tolerance test (OGTT) will be performed at baseline and 6 months after treatment onset. An overall study duration of 12 months is proposed.\n\nMaterials and Methods: MRI measurements will be performed on a 3 Tesla scanner. Study population: 10 FtM, 10 male-to-female MtF transsexuals (aged 18-50), free of hormone-medication at baseline. Relevance and implications of the study: Changes in atherosclerotic risk due to hormone therapy have been studied to no definite results and so far, little is known about the effects of hormone therapy on hepatic and myocardial fatty tissue. Hence this study will provide important new data on the broad clinical aspects of sex hormones as hormone replacement therapy in particularly opposite-sex hormone therapy.",[78],"Gender Dysphoria","2025-09-29",{"date":81,"type":82},"2025-10-03","ACTUAL",{"date":84,"type":82},"2017-10-20",{"date":86,"type":74},"2028-10-20",{"name":5,"class":6},1]